Increased prevalence of regurgitant valvular heart disease in acromegaly.
暂无分享,去创建一个
Jeroen J. Bax | E. E. van der Wall | J. Romijn | F. Roelfsema | J. Lindner | J. Smit | H. Morreau | S. V. van Thiel | A. Pereira
[1] D. Bonaduce,et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. , 2003, The Journal of clinical endocrinology and metabolism.
[2] C. Mady,et al. Treatment of acromegaly improves myocardial abnormalities. , 2002, American heart journal.
[3] P. Libby,et al. Activated Interstitial Myofibroblasts Express Catabolic Enzymes and Mediate Matrix Remodeling in Myxomatous Heart Valves , 2001, Circulation.
[4] E. Creemers,et al. This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinase: Regulation and Dysregulation in the failing Heart Matrix M , 2022 .
[5] S. Tyagi,et al. Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength. , 2001, International journal of cardiology.
[6] B. Howard,et al. Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study. , 2001, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[7] B. Thompson,et al. Identification of genes induced by growth hormone in rat liver using cDNA arrays. , 2000, Endocrinology.
[8] J. Shirani,et al. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. , 2000, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[9] F. Franco,et al. Acromegalia asociada a prolapso mitral y tricuspídeo. Descripción de un caso , 2000 .
[10] F. Sánchez Franco,et al. [Acromegaly associated with mitral and tricuspid prolapse. Report of a case]. , 2000, Revista espanola de cardiologia.
[11] A. Burger,et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. , 1999, Journal of the American College of Cardiology.
[12] M. Salvatore,et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. , 1999, The Journal of clinical endocrinology and metabolism.
[13] Jagmeet P. Singh,et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) , 1999, The American journal of cardiology.
[14] A. Colao,et al. Bone mineral density and circulating cytokines in patients with acromegaly , 1998, Journal of endocrinological investigation.
[15] N. Weissman,et al. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. , 1998, The New England journal of medicine.
[16] Y. Tomizawa,et al. Heart valve operation in acromegaly. , 1997, The Annals of thoracic surgery.
[17] P. Marzullo,et al. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. , 1997, The Journal of endocrinology.
[18] P. Wrightson,et al. Determinants of clinical outcome and survival in acromegaly , 1994, Clinical endocrinology.
[19] K. Isaaz,et al. A simplified normalized ejection phase index measured by Doppler echocardiography for the assessment of left ventricular performance. , 1990, The American journal of cardiology.
[20] N C Nanda,et al. Evaluation of aortic insufficiency by Doppler color flow mapping. , 1987, Journal of the American College of Cardiology.
[21] N. Nanda,et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. , 1987, Circulation.
[22] A. Jaffe,et al. Mitral Valve Prolapse: A Consistent Manifestation of Type IV Ehlers‐Danlos Syndrome The Pathogenetic Role of the Abnormal Production of Type III Collagen , 1981, Circulation.